These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer. Wang H; Lv Q; Xu Y; Cai Z; Zheng J; Cheng X; Dai Y; Jänne PA; Ambrogio C; Köhler J EBioMedicine; 2019 Nov; 49():106-117. PubMed ID: 31668570 [TBL] [Abstract][Full Text] [Related]
5. Targeting KRAS for the potential treatment of pancreatic ductal adenocarcinoma: Recent advancements provide hope (Review). Zhang J; Darman L; Hassan MS; Von Holzen U; Awasthi N Oncol Rep; 2023 Nov; 50(5):. PubMed ID: 37800636 [TBL] [Abstract][Full Text] [Related]
6. Hexachlorophene, a selective SHP2 inhibitor, suppresses proliferation and metastasis of KRAS-mutant NSCLC cells by inhibiting RAS/MEK/ERK and PI3K/AKT signaling pathways. Fu NJ; Xi RY; Shi XK; Li RZ; Zhang ZH; Li LY; Zhang GL; Wang F Toxicol Appl Pharmacol; 2022 Apr; 441():115988. PubMed ID: 35307375 [TBL] [Abstract][Full Text] [Related]
7. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer. Vakana E; Pratt S; Blosser W; Dowless M; Simpson N; Yuan XJ; Jaken S; Manro J; Stephens J; Zhang Y; Huber L; Peng SB; Stancato LF Oncotarget; 2017 Feb; 8(6):9251-9266. PubMed ID: 27999210 [TBL] [Abstract][Full Text] [Related]
8. Kirsten rat sarcoma viral oncogene homolog G12C mutant advanced non-small-cell lung cancer treated with MEK1/2 inhibitor trametinib: a case report. Jiang Y; Liu X; Lv DL; Zhao XL Anticancer Drugs; 2022 Jan; 33(1):e752-e755. PubMed ID: 34387588 [TBL] [Abstract][Full Text] [Related]
9. Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition. Vaclova T; Chakraborty A; Sherwood J; Ross S; Carroll D; Barrett JC; Downward J; de Bruin EC Sci Rep; 2022 Feb; 12(1):2699. PubMed ID: 35177674 [TBL] [Abstract][Full Text] [Related]
10. Amplification of Wild-type Bahcall M; Awad MM; Sholl LM; Wilson FH; Xu M; Wang S; Palakurthi S; Choi J; Ivanova EV; Leonardi GC; Ulrich BC; Paweletz CP; Kirschmeier PT; Watanabe M; Baba H; Nishino M; Nagy RJ; Lanman RB; Capelletti M; Chambers ES; Redig AJ; VanderLaan PA; Costa DB; Imamura Y; Jänne PA Clin Cancer Res; 2018 Dec; 24(23):5963-5976. PubMed ID: 30072474 [TBL] [Abstract][Full Text] [Related]
11. Combined targeting of EGFR/HER promotes anti-tumor efficacy in subsets of KRAS mutant lung cancer resistant to single EGFR blockade. Umelo IA; De Wever O; Kronenberger P; Van Deun J; Noor A; Singh K; Teugels E; Chen G; Bracke M; De Grève J Oncotarget; 2015 Aug; 6(24):20132-44. PubMed ID: 25992771 [TBL] [Abstract][Full Text] [Related]
12. Does Molecular Profiling of Karim NA; Ullah A; Pathrose P; Fathallah H; Perry A; Morris JC; Wang J; Starnes SL Curr Oncol; 2022 Jul; 29(7):4779-4790. PubMed ID: 35877239 [TBL] [Abstract][Full Text] [Related]
13. Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells. Chen J; Bi H; Hou J; Zhang X; Zhang C; Yue L; Wen X; Liu D; Shi H; Yuan J; Liu J; Liu B Cell Death Dis; 2013 Sep; 4(9):e814. PubMed ID: 24071646 [TBL] [Abstract][Full Text] [Related]
14. Vincristine Enhances the Efficacy of MEK Inhibitors in Preclinical Models of KRAS-mutant Colorectal Cancer. Ghosh S; Fan F; Powell RT; Roszik J; Park YS; Stephan C; Sebastian M; Tan L; Sorokin AV; Lorenzi PL; Kopetz S; Ellis LM; Bhattacharya R Mol Cancer Ther; 2023 Aug; 22(8):962-975. PubMed ID: 37310170 [TBL] [Abstract][Full Text] [Related]
15. Selumetinib in advanced non small cell lung cancer (NSCLC) harbouring KRAS mutation: endless clinical challenge to KRAS-mutant NSCLC. Paolo M; Assunta S; Antonio R; Claudia SP; Anna BM; Clorinda S; Francesca C; Fortunato C; Cesare G Rev Recent Clin Trials; 2013 Jun; 8(2):93-100. PubMed ID: 24063423 [TBL] [Abstract][Full Text] [Related]
16. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches. Reck M; Carbone DP; Garassino M; Barlesi F Ann Oncol; 2021 Sep; 32(9):1101-1110. PubMed ID: 34089836 [TBL] [Abstract][Full Text] [Related]
17. A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†. Blumenschein GR; Smit EF; Planchard D; Kim DW; Cadranel J; De Pas T; Dunphy F; Udud K; Ahn MJ; Hanna NH; Kim JH; Mazieres J; Kim SW; Baas P; Rappold E; Redhu S; Puski A; Wu FS; Jänne PA Ann Oncol; 2015 May; 26(5):894-901. PubMed ID: 25722381 [TBL] [Abstract][Full Text] [Related]
18. Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells. Takezawa K; Okamoto I; Yonesaka K; Hatashita E; Yamada Y; Fukuoka M; Nakagawa K Cancer Res; 2009 Aug; 69(16):6515-21. PubMed ID: 19638574 [TBL] [Abstract][Full Text] [Related]
19. Editorial: Recent Approval of Sotorasib as the First Targeted Therapy for KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC). Parums DV Med Sci Monit; 2022 Nov; 28():e938746. PubMed ID: 36317327 [TBL] [Abstract][Full Text] [Related]